Actively Recruiting

Phase Not Applicable
All Genders
ID05629130

Embolization in Hereditary Coagulopathies to Treat Arthropathy and Chronic Synovitis

Led by University of Sao Paulo General Hospital · Updated on 2022-11-29

30

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

Sponsors

U

University of Sao Paulo General Hospital

Lead Sponsor

M

Merit Medical Systems, Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research aims to study 30 people with hereditary coagulopathies who have joint problems and chronic synovitis caused by bleeding into the elbows, knees, and/or ankles. These participants are followed at the Hemophilia Center of the University of Sao Paulo's Hospital after ethical approval. The study evaluates these patients over a long period to understand the effects of a specific embolization treatment on their joint health and quality of life. Participants will receive a superselective embolization procedure using spherical microparticles called Embosphere to target arteries in the affected joints. This treatment aims to cause partial blood flow blockage and reduce abnormal synovial tissue enhancement. The study includes imaging tests such as X-rays and magnetic resonance imaging (MRI) of the affected joints, alongside functional and quality of life assessments. Assessments will be done at the start and then at 1, 3, 6, 12, 24, 36, 48, and 60 months after the embolization procedure. These include measuring synovium thickness, synovitis, muscle strength, balance, fall risk, pain, stiffness, physical function, and quality of life through various scales and questionnaires. This thorough follow-up will help researchers monitor changes and safety over five years.

CONDITIONS

Brief Title

Embolization in Hereditary Coagulopathies

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with hereditary coagulopathies with arthropathy, including chronic synovitis due to hemarthrosis
  • X-ray and MRI confirming synovitis of the affected joints
  • Patients followed up at the Hemophilia Center HC-FMUSP
Not Eligible

You will not qualify if you...

  • Patients who do not complete the planned assessments
  • Patients who do not accept to continue with the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Day of procedure

Participants undergo the embolization procedure on the affected joint(s) using spherical microparticles Embosphere to reduce synovitis.

1 visit (in-person)

Long-term Monitoring

Duration - 60 months

Participants are followed up with regular assessments including imaging, physical and functional tests, pain evaluation, and quality of life questionnaires to monitor treatment effects and joint health.

Visits at 1, 3, 6, 12, 24, 36, 48, and 60 months after the procedure

Trial Site Locations

Total: 1 location

1

Instituto de Ortopedia e Traumatologia do Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo

São Paulo, Brazil, 05403-010

Actively Recruiting

Loading map...

Research Team

M

marcia u rezende, MD PhD

F

Fabiane E Farias, PT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here